X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Torrent Pharma Fact Sheet, Torrent Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Torrent Pharma Fact Sheet   (TORR)

Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

TORRENT PHARMA Price History

Price Rs 1,271.6
Mkt Cap Rs m 215,231
Vol '000 5.2
P/E X 23.0
P/CF X 10.9
EPS (TTM) Rs 55.2
% ch % -0.1
No. of shares m 169.26
% ch week % -0.3
% ch 1-mth % 7.5
% ch 12-mth % -9.8
52 week H/L Rs 1,767.8/1,143.5
(As on Jul 27, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

TORRENT PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
TORRENT PHARMA EQUITY SHARE DATA
High Rs6877675781,2321,720 
Low Rs4995973345231,134 
Sales per share (Unadj.) Rs318.6379.5247.3275.0394.5 
Earnings per share (Unadj.) Rs33.651.139.244.4101.8 
Diluted earnings per shareRs16.825.639.244.4101.8 
Cash flow per share (Unadj.) Rs43.260.944.455.6116.3 
Dividends per share (Unadj.) Rs8.5023.0010.0011.2540.00 
Adj. dividends per shareRs4.2511.5010.0011.2539.99 
Dividend yield (eoy) %1.43.42.21.32.8 
Book value per share (Unadj.) Rs141.1168.1112.4147.2200.3 
Adj. book value per shareRs70.584.0112.4147.1200.2 
Shares outstanding (eoy) m84.6184.61169.22169.22169.22 
Bonus/Rights/Conversions  --B1:1-- 
Price / Sales ratio x1.91.81.83.23.6 
Avg P/E ratio x17.713.311.619.814.0 
P/CF ratio (eoy) x13.711.210.315.812.3 
Price / Book Value ratio x4.24.14.16.07.1 
Dividend payout %25.345.025.525.439.3 
Avg Mkt Cap Rs m50,17457,70477,190148,465241,435 
No. of employees `0009.29.69.511.010.9 
Total wages/salary Rs m5,3186,2337,4118,4188,559 
Avg. sales/employee Rs Th2,946.43,354.04,386.54,212.46,129.6 
Avg. wages/employee Rs Th581.2651.0776.8762.0785.8 
Avg. net profit/employee Rs Th310.4452.0695.9679.81,581.3 
TORRENT PHARMA INCOME DATA
Net Sales Rs m26,95932,11141,84746,53566,764 
Other income Rs m4454343812,8562,156 
Total revenues Rs m27,40432,54542,22949,39068,920 
Gross profit Rs m5,0066,9229,51510,20227,204 
Depreciation Rs m8178278701,9072,461 
Interest Rs m3953385861,7521,859 
Profit before tax Rs m4,2406,1918,4409,39825,041 
Minority Interest Rs m-23-22000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-654-37500-1,403 
Tax Rs m7231,4671,8011,8886,414 
Profit after tax Rs m2,8404,3286,6397,50917,224 
Gross profit margin %18.621.622.721.940.7 
Effective tax rate %17.123.721.320.125.6 
Net profit margin %10.513.515.916.125.8 
TORRENT PHARMA BALANCE SHEET DATA
Current assets Rs m19,87125,60934,04540,51446,622 
Current liabilities Rs m13,62817,10721,74628,23832,843 
Net working cap to sales %23.226.529.426.420.6 
Current ratio x1.51.51.61.41.4 
Inventory Days Days72105888474 
Debtors Days Days71789612579 
Net fixed assets Rs m9,15711,05114,09534,95139,029 
Share capital Rs m423423846846846 
"Free" reserves Rs m11,45313,63417,27222,94331,400 
Net worth Rs m11,93814,21919,02424,90633,890 
Long term debt Rs m3,2214,5457,44521,85218,637 
Total assets Rs m30,59737,83950,69879,03890,136 
Interest coverage x11.719.315.46.414.5 
Debt to equity ratio x0.30.30.40.90.5 
Sales to assets ratio x0.90.80.80.60.7 
Return on assets %10.612.314.311.721.2 
Return on equity %23.830.434.930.250.8 
Return on capital %26.132.734.123.848.5 
Exports to sales %28.137.737.430.443.3 
Imports to sales %8.27.68.26.06.9 
Exports (fob) Rs m7,58512,11415,66514,13628,934 
Imports (cif) Rs m2,2082,4333,4162,8014,584 
Fx inflow Rs m8,15013,22816,86214,26529,185 
Fx outflow Rs m3,5484,7345,1965,1846,021 
Net fx Rs m4,6038,49411,6669,08123,165 
TORRENT PHARMA CASH FLOW
From Operations Rs m 4,991 1,535 5,994 8,102 27,132 
From Investments Rs m -1,370 -2,417 -3,558 -21,623 -7,014 
From Financial Activity Rs m -1,927 197 864 12,123 -14,352 
Net Cashflow Rs m 1,694 -685 3,300 -1,399 5,767 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 71.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 7.0%
FIIs 12.6%
ADR/GDR 0.0%
Free float 8.8%
Shareholders 26,511
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Torrent House, Off Ashram Road, Ahmedabad - 380 009
E-MAIL maheshagrawal@torrentpharma.com WEB www.torrentpharma.com
TELEPHONE (079) 2658 5090 FAX (079) 2658 2100
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Deloitte Haskins & Sells
CHM: Sudhir Mehta COMP SEC: Mahesh Agarwal YEAR OF INC: 1973 BSE CODE: 500420 FV (Rs): 5 DIV YIELD (%): 3.1

More Pharmaceuticals Company Fact Sheets:   BIOCON LTD  AMAR REMEDIES  TTK HEALTHCARE  DR. REDDYS LAB  ALKEM LABORATORIES  

Compare TORRENT PHARMA With:   BIOCON LTD  AMAR REMEDIES  TTK HEALTHCARE  DR. REDDYS LAB  ALKEM LABORATORIES  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Flat in Final Hour Sell Off; HDFC Twins Surge(Closing)

Indian share markets witnessed selling pressure in the final hour of trade but still closed at a record high for a third straight session.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

Trade the Markets like Roger Federer Plays Tennis(Daily Profit Hunter)

Jul 19, 2017

Trading is one of the most competitive fields in the world today. To win, you must adopt the mindset of a Grand Slam champion.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

Why Keeping Unrealistic Expectations From Investments Is Stupid!(Outside View)

Jul 18, 2017

When investing, keeping realistic returns is necessary and it is not the only thing you should look at.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS